In CRC animal models, TRC105 treatment reduced Treg numbers in tumors, and the combination of TRC105 with PD-1 inhibitors significantly enhanced the efficacy of PD-1 inhibitors in CRC models (subcutaneous, orthotopic, and chemically induced) (104). Here, PDCD1 is linked to colorectal carcinoma.